261 related articles for article (PubMed ID: 33247879)
1. Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Ghosh I; Mukhopadhyay P; Das K; Anne M B; Ali Mondal S; Basu M; Nargis T; Pandit K; Chakrabarti P; Ghosh S
J Diabetes; 2021 Jun; 13(6):506-511. PubMed ID: 33247879
[TBL] [Abstract][Full Text] [Related]
2. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
[No Abstract] [Full Text] [Related]
3. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
4. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
[TBL] [Abstract][Full Text] [Related]
5. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
6. Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea.
Matsumoto T; Harada N; Azuma M; Chihara Y; Murase K; Tachikawa R; Minami T; Hamada S; Tanizawa K; Inouchi M; Oga T; Mishima M; Chin K
Ann Am Thorac Soc; 2016 Aug; 13(8):1378-87. PubMed ID: 27104640
[TBL] [Abstract][Full Text] [Related]
7. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
9. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
10. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
Ryskjaer J; Deacon CF; Carr RD; Krarup T; Madsbad S; Holst J; Vilsbøll T
Eur J Endocrinol; 2006 Sep; 155(3):485-93. PubMed ID: 16914604
[TBL] [Abstract][Full Text] [Related]
11. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
12. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.
Laferrère B; Teixeira J; McGinty J; Tran H; Egger JR; Colarusso A; Kovack B; Bawa B; Koshy N; Lee H; Yapp K; Olivan B
J Clin Endocrinol Metab; 2008 Jul; 93(7):2479-85. PubMed ID: 18430778
[TBL] [Abstract][Full Text] [Related]
13. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
[TBL] [Abstract][Full Text] [Related]
14. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
[TBL] [Abstract][Full Text] [Related]
15. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
16. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
17. Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Østoft SH; Bagger JI; Hansen T; Hartmann B; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2015 Aug; 173(2):205-15. PubMed ID: 25953829
[TBL] [Abstract][Full Text] [Related]
18. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
20. Impact of incretin on early-phase insulin secretion and glucose excursion.
Shen J; Chen Z; Chen C; Zhu X; Han Y
Endocrine; 2013 Oct; 44(2):403-10. PubMed ID: 23283820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
